ASKA Pharmaceutical Holdings (4886) · FactUpdated customer concentration ratio
Pharmaceutical Sales Through Takeda Pharmaceutical Company Limited
First written in FY2022-Q1. 5 of 7 entries say "Restated". Latest entry: FY2026.
7entries
6years
0from disclosures
How it moved
Same theme, other companies
Concentration of sales through Takeda PharmaceuticalA theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2026Updated customer concentration ratioAnnual report
「Takeda Pharmaceutical Company Limited ¥57,155 million 80.4%」
Sales through Takeda Pharmaceutical Company Limited amounted to ¥57,155 million, representing 80.4% of total sales. The ratio declined from 86.5% in the previous fiscal year. - FY2024RestatedAnnual report
「武田薬品工業㈱ 54,564 86.8」
武田薬品工業株式会社向け販売は54,564百万円、総販売実績の86.8％となっており、同社を通じた販売構造を再確認している。 - FY2023RestatedAnnual report
「武田薬品工業㈱ 52,293 86.5」
武田薬品工業株式会社を通じた販売が52,293百万円、総販売実績の86.5％を占めたことを記載している。 - FY2022RestatedAnnual report
「武田薬品工業㈱ 49,439百万円 87.3％」
武田薬品工業株式会社向け販売が49,439百万円、総販売実績の87.3％を占めるという販売経路の実績を記載している。 - FY2022-Q3RestatedAnnual report
「Pharmaceuticals business: manufactured or procured by Asuka Pharmaceutical Co., Ltd. and sold mainly through Takeda Pharmaceutical Company Limited.」
あすか製薬株式会社が製造・仕入れを行い、主に武田薬品工業株式会社を通じて販売する経路を再掲している。 - FY2022-Q2RestatedAnnual report
「Pharmaceuticals business: manufactured or procured by Asuka Pharmaceutical Co., Ltd. and sold mainly through Takeda Pharmaceutical Company Limited.」
医薬品の製造・仕入れと、主に武田薬品工業を通じた販売経路を再掲している。 - FY2022-Q1First statedAnnual report
「Pharmaceuticals business: manufactured or procured by Asuka Pharmaceutical Co., Ltd. and sold mainly through Takeda Pharmaceutical Company Limited.」
Takeda Pharmaceutical Company Limited is identified as the main sales channel for the pharmaceuticals business.